Louis B. Harrison, MD, of the Moffitt Cancer Center, discusses radiation oncology in the context of personalized medicine, multidisciplinary care, new technology and applications, and the mandate to contain costs.
Thomas J. Lynch, Jr, MD, of Massachusetts General Hospital, summarizes his keynote lecture on whether we are any closer to curing lung cancer with targeted treatments. (Keynote Address 2)
Howard M. Sandler, MD, of Cedars-Sinai Medical Center, discusses prospective clinical trials as the gold standard of clinical decision-making and examines the infrastructure needed for future cancer research. (Abstract PS 3)
Maria Werner-Wasik, MD, of Thomas Jefferson University Hospital, summarizes a session she moderated on lung toxicity, including the impact of cardiac radiation, the risk of radiation to thoracic vertebral bodies, radiation pneumonitis, and upfront SBRT. (Scientific Session 39)
Paul L. Nguyen, MD, of the Dana-Farber Cancer Institute, summarizes a session he moderated, which included talks on local recurrence following brachytherapy, long-term PSA stability after the procedure, and androgen deprivation and high-dose radiotherapy. (Scientific Session 41)
Joanne B. Weidhaas, MD, PhD, of the University of California, Los Angeles Radiation Oncology, discusses the KRAS variant as a biomarker of cetuximab response and altered immunity in head and neck cancer. (Abstract LBA-11)
